Document:

<PAGE>
                                                                 EXHIBIT 10.19

         THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH
RULE 144 UNDER SAID ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED
THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, SATISFACTORY TO THE COMPANY,
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE .ACT OR RECEIPT OF A NO-ACTION
LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION.

                         ------------------------------

         WARRANT TO PURCHASE 54,000 SHARES SERIES B PREFERRED STOCK

                                                                   July 20 ,1995

         THIS CERTIFIES THAT, for value received, Lease Management Services,
Inc., ("Holder") is entitled to subscribe for and purchase fifty four thousand
(54,000) shares of the fully paid and nonassessable Series B Preferred Stock
("the Shares") of IntraBiotics Pharmaceuticals, Inc., a Delaware corporation
(the "Company"), at the Warrant Price (as hereinafter defined), subject to the
provisions and upon the terms and conditions hereinafter set forth. As used
herein, the term "Series B Preferred Stock" shall mean the Company's presently
authorized Series B Preferred Stock, and any stock into which such Series B
Preferred Stock may hereafter be exchanged.

1. WARRANT PRICE. The Warrant Price shall initially be one and 00/100 dollars
($1.00), subject to adjustment as provided in Section 7 below.

2. CONDITIONS TO EXERCISE. The purchase right represented by this Warrant may be
exercised at any time, or from time to time, in whole or in part during the term
commencing on the date hereof and ending on the earlier of:

         (a) 5:00 P.M. California time on the sixth annual anniversary of this
Warrant; or

         (b) the effective date of the merger of the Company with or into, the
consolidation of the Company with, or the sale by the Company of all or
substantially all of its assets to another corporation or other entity (other
than such a transaction wherein the shareholders of the Company retain or obtain
a majority of the voting capital stock of the surviving, resulting, or
purchasing corporation); provided that the Company shall notify the registered
Holder of this Warrant of the proposed effective date of the merger,
consolidation, or sale at least 60 days prior to the effectiveness thereof.

         In the event that, although the Company shall have given notice of a
transaction pursuant to subparagraph (b) hereof, the transaction does not close
on approximately the day specified by the Company, unless otherwise elected by
the Holder any exercise of the Warrant subsequent to the giving of such notice
shall be rescinded and the Warrant shall again be exercisable until terminated
in accordance with this Paragraph 2.

                                       1.

<PAGE>

3. METHOD OF EXERCISE; PAYMENT; ISSUANCE OF SHARES; ISSUANCE OF NEW WARRANT.

         (a) CASH EXERCISE. Subject to Section 2 hereof, the purchase right
represented by this Warrant may be exercised by the Holder hereof, in whole or
in part, by the surrender of this Warrant (with a duly executed Notice of
Exercise in the form attached hereto) at the principal office of the Company (as
set forth in Section 18 below) and by payment to the Company, by check, of an
amount equal to the then applicable Warrant Price per share multiplied by the
number of shares then being purchased. In the event of any exercise of the
rights represented by this Warrant, certificates for the shares of stock so
purchased shall be in the name of, and delivered to, the Holder hereof, or as
such Holder may direct (subject to the terms of transfer contained herein and
upon payment by such Holder hereof of any applicable transfer taxes). Such
delivery shall be made within 10 days after exercise of the Warrant and at the
Company's expense and, unless this Warrant has been fully exercised or expired,
a new Warrant having terms and conditions substantially identical to this
Warrant and representing the portion of the Shares, if any, with respect to
which this Warrant shall not have been exercised, shall also be issued to the
Holder hereof within 10 days after exercise of the Warrant.

         (b) NET ISSUE EXERCISE. In lieu of exercising this Warrant pursuant to
Section 3(a), Holder may elect to receive shares equal to the value of this
Warrant (or of any portion thereof remaining unexercised) by surrender of this
Warrant at the principal office of the Company together with notice of such
election, in which event the Company shall issue to Holder the number of shares
of the Company's Series B Preferred Stock computed using the following formula:

         X = Y (A-B)
             -------
                A

         Where X = the number of shares of Series B Preferred Stock to be issued
                   to Holder.

         Y = the number of shares of Series B Preferred Stock purchasable
             under this Warrant (at the date of such calculation).

         A = the fair market value of one share of the Company's Series B
             Preferred Stock (at the date of such calculation).

         B = Warrant exercise price (as adjusted to the date of such
             calculation).

         (c) FAIR MARKET VALUE. For purposes of this Section 3, Fair Market
Value of one share of the Company's Series B Preferred Stock shall mean:

                  (i) In the event of an Initial Public Offering per share Fair
Market Value for the Series B Preferred Stock shall be the Offering Price at
which the underwriters sell Common Stock to the public multiplied by the number
of shares of Common Stock into which each share of Series B Preferred Stock is
then convertible; or

                  (ii) If the Common Stock is traded on NASDAQ or
Over-The-Counter or on an exchange, the per share Fair Market Value for the
Series B Preferred Stock will be the average of the closing bid and asked prices
of the Common Stock quoted in the Over-The-

                                       2.

<PAGE>

Counter Market Summary or the closing price quoted on any exchange on which the
Series B Preferred Stock is listed, whichever is applicable, as published in the
Western Edition of The Wall Street Journal for the ten (10) trading days prior
to the date of determination of Fair Market Value multiplied by the number of
shares of Common Stock into which each share of Series B Preferred Stock is then
convertible; or

                  (iii) If the Company shall be subject to a merger, acquisition
or other consolidation in which the Company is not the surviving entity,
pursuant to Section 200), the per share Fair Market Value for the Series B
Preferred Stock shall be the value received per share of Series B Preferred
Stock by all Holders of the Series B Preferred Stock as determined by the Board
of Directors; or

                  (iv) In any other instance, the per share Fair Market Value
for the Series B Preferred Stock shall be as determined by the Board of
Directors in its reasonable business judgment.

         In the event of 3(c)(iii) or 3(c)(iv), above, the Company's Board of
Directors shall prepare a certificate, to be signed by an authorized Officer of
the Company, setting forth in reasonable detail the basis for and method of
determination of the per share Fair Market Value of the Series B Preferred
Stock. The Board will also certify to the Holder that this per share Fair Market
Value will be applicable to all holders of the Company's Series B Preferred
Stock. Such certification must be made to Holder at least thirty (30) business
days prior to the proposed effective date of the merger, consolidation, sale, or
other triggering event as defined in 3(c)(iii) and 3(c)(iv).

         (d) AUTOMATIC EXERCISE. To the extent this Warrant is not previously
exercised, it shall be automatically exercised in accordance with Sections 3(b)
and 3(c) hereof (even if not surrendered) immediately before: (i) its
expiration, or (ii) the consummation of any consolidation or merger of the
Company, or any sale or transfer of a majority of a company's assets pursuant to
Section 2(b).

4. REPRESENTATIONS AND WARRANTIES OF HOLDER AND RESTRICTIONS ON TRANSFER IMPOSED
BY THE SECURITIES ACT OF 1933.

         (a) REPRESENTATIONS AND WARRANTIES BY HOLDER. The Holder represents and
warrants to the Company with respect to this purchase as follows:

                  (i) The Holder has substantial experience in evaluating and
investing in private placement transactions of securities of companies similar
to the Company so that the Holder is capable of evaluating the merits and risks
of its investment in the Company and has the capacity to protect its interests.

                  (ii) The Holder is acquiring the Warrant and the Shares of
Series B Preferred Stock issuable upon exercise of the Warrant (collectively the
"Securities") for investment for its own account and not with a view to, or for
resale in connection with, any distribution thereof. The Holder understands that
the Securities have not been registered under the Act by reason of a specific
exemption from the registration provisions of the Act which depends upon, among
other things, the bona fide nature of the investment intent as expressed herein.
In this connection, the

                                       3.

<PAGE>

Holder understands that, in the view of the Securities and Exchange Commission
(the "SEC"), the statutory basis for such exemption may be unavailable if this
representation was predicated solely upon a present intention to hold the
Securities for the minimum capital gains period specified under tax statutes,
for a deferred sale, for or until an increase or decrease in the market price of
the Securities or for a period of one year or any other fixed period in the
future.

                  (iii) The Holder acknowledges that the Securities must be held
indefinitely unless subsequently registered under the Act or an exemption from
such registration is available. The Holder is aware of the provisions of Rule
144 promulgated under the Act ("Rule 144") which permits limited resale of
securities purchased in a private placement subject to the satisfaction of
certain conditions, including, in case the securities have been held for less
than three years, the existence of a public market for the shares, the
availability of certain public information about the Company, the resale
occurring not less than two years after a party has purchased and paid for the
security to be sold, the sale being through a "broker's transaction" or in a
transaction directly with a "market maker" (as provided by Rule 144(f)) and the
number of shares or other securities being sold during any three-month period
not exceeding specified limitations.

                  (iv) The Holder further understands that at the time the
Holder wishes to sell the Securities there may be no public market upon which
such a sale may be effected, and that even if such a public market exists, the
Company may not be satisfying the current public information requirements of
Rule 144, and that in such event, the Holder may be precluded from selling the
Securities under Rule 144 unless as a three-year minimum holding period has been
satisfied and b) the Holder was not at the time of the sale nor at any time
during the three-month period prior to such sale an affiliate of the Company.

                  (v) The Holder has had an opportunity to discuss the Company's
business, management and financial affairs with its management and an
opportunity to review the Company's facilities. The Holder understands that such
discussions, as well as the written information issued by the Company, were
intended to describe the aspects of the Company's business and prospects which
it believes to be material but were not necessarily a thorough or exhaustive
description.

         (b) LEGENDS. Each certificate representing the Securities shall be
endorsed with the following legend:

         THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
         1933 AND MAY NOT BE TRANSFERRED UNLESS COVERED BY AN EFFECTIVE
         REGISTRATION STATEMENT UNDER SAID ACT, A "NO ACTION" LETTER FROM THE
         SECURITIES AND EXCHANGE COMMISSION WITH RESPECT TO SUCH TRANSFER, A
         TRANSFER MEETING THE REQUIREMENTS OF RULE 144 OF THE SECURITIES AND
         EXCHANGE COMMISSION, OR AN OPINION OF COUNSEL SATISFACTORY TO THE
         ISSUER TO THE EFFECT THAT ANY SUCH TRANSFER IS EXEMPT FROM SUCH
         REGISTRATION.

                                       4.

<PAGE>

         The Company need not register a transfer of Securities unless the
conditions specified in the foregoing legend are satisfied. The Company may also
instruct its transfer agent not to register the transfer of any of the Shares
unless the conditions specified in the foregoing legend are satisfied.

         (c) REMOVAL OF LEGEND AND TRANSFER RESTRICTIONS. The legend relating to
the Act endorsed on a certificate pursuant to paragraph 4(b) of this Warrant and
the stop transfer instructions with respect to the Securities represented by
such certificate shall be removed and the Company shall issue a certificate
without such legend to the Holder of the Securities if (i) the Securities are
registered under the Act and a prospectus meeting the requirements of Section 10
of the Act is available or (ii) the Holder provides to the Company an opinion of
counsel for the Holder reasonably satisfactory to the Company, or a no-action
letter or interpretive opinion of the staff of the SEC reasonably satisfactory
to the Company, to the effect that public sale, transfer or assignment of the
Securities may be without registration and without compliance with any
restriction such as Rule 144.

5. CONDITION OF TRANSFER OR EXERCISE OF WARRANT. It shall be a condition to any
transfer or exercise of this Warrant that at the time of such transfer or
exercise, the Holder shall provide the Company with a representation in writing
that the Holder or transferee is acquiring this Warrant and the shares of Series
B Preferred Stock to be issued upon exercise, for investment purposes only and
not with a view to any sale or distribution, or a statement of pertinent facts
coveting any proposed distribution. As a further condition to any transfer of
this Warrant or any or all of the shares of Series B Preferred Stock issuable
upon exercise of this Warrant, other than a transfer registered under the Act,
the Company must have received a legal opinion, in form and substance
satisfactory to the Company and its counsel, reciting the pertinent
circumstances surrounding the proposed transfer and stating that such transfer
is exempt from the registration and prospectus delivery requirements of the Act.
Each certificate evidencing the shares issued upon exercise of the Warrant or
upon any transfer of the shares (other than a transfer registered under the Act
or any subsequent transfer of shares so registered) shall, at the Company's
option, contain a legend in form and substance satisfactory to the Company and
its counsel, restricting the transfer of the shares to sales or other
dispositions exempt from the requirements of the Act.

         As further condition to each transfer, the transferee shall receive and
accept a Warrant, of like tenor and date, executed by the Company.

6. STOCK FULLY PAID; RESERVATION OF SHARES. All Shares which may be issued upon
the exercise of the rights represented by this Warrant will, upon issuance, be
fully paid and nonassessable, and free from all taxes, liens, and charges with
respect to the issue thereof. During the period within which the rights
represented by this Warrant may be exercised, the Company will at all times have
authorized, and reserved for issuance upon exercise of the purchase rights
evidenced by this Warrant, a sufficient number of shares of its Series B
Preferred Stock to provide for the exercise of the rights represented by this
Warrant.

7. ADJUSTMENT FOR CERTAIN EVENTS. In the event of changes in the outstanding
Series B Preferred Stock by reason of stock dividends, split-ups,
recapitalizations, reclassifications, conversions, mergers, consolidations,
combinations or exchanges of shares, separations, reorganizations, liquidations,
or the like, the number and class of shares available under the

                                       5.

<PAGE>

Warrant in the aggregate and the Warrant Price shall be correspondingly
adjusted, as appropriate, by the Board of Directors of the Company. The
adjustment shall be such as will give the Holder of this Warrant upon exercise
for the same aggregate Warrant Price the total number, class and kind of shares
as it would have owned had the Warrant been exercised prior to the event and had
it continued to hold such shares until after the event requiring adjustment.
Nothing herein shall be construed as providing Holder with antidilution rights
greater than the antidilution rights, if any, of the holders of the Series B
Preferred Stock generally, as set forth in the Company's Restated Articles of
Incorporation, as amended. No adjustment in the Warrant Price and/or the number
of Shares need be made if such adjustment would result in a change in the
Warrant Price of less than one cent ($0.01) or a change in the number of Shares
of less than one-hundredth (1/100th) of a share. Any adjustment less than these
amounts which is not made shall be carried forward and shall be made at the time
and together with any subsequent adjustment which, on a cumulative basis,
amounts to an adjustment of at least these amounts.

8. NOTICE OF ADJUSTMENTS. Whenever any Warrant Price shall be adjusted pursuant
to Section 7 hereof, the Company shall prepare a certificate signed by its chief
financial officer setting forth, in reasonable detail, the event requiring the
adjustment, the amount of the adjustment, the method by which such adjustment
was calculated, and the Warrant Price and number of shares issuable upon
exercise of the Warrant after giving effect to such adjustment, and shall cause
copies of such certificate to be mailed (by certified or registered mail, return
receipt required, postage prepaid) within thirty (30) days of such adjustment to
the Holder of this warrant as set forth in Section 18 hereof.

9. "MARKET STAND-OFF" AGREEMENT. Holder hereby agrees that for a period of 180
days following the effective date of the first registration statement of the
Company covering Series B Preferred stock (or other securities) to be sold on
its behalf in an underwritten public offering, it will not, to the extent
requested by the Company and any underwriter, sell or otherwise transfer or
dispose of (other than to donees or transferees who agree to be similarly bound)
any of the Shares at any time during such period except Series B Preferred stock
included in such registration; provided, however, that all officers and
directors of the Company who hold securities of the Company or options to
acquire securities of the Company and all other persons with registration rights
enter into similar agreements.

10. TRANSFERABILITY OF WARRANT. This Warrant is transferable one time only, in
whole and not in part, on the books of the Company at its principal office by
the registered Holder hereof upon surrender of this Warrant properly endorsed,
subject to compliance with applicable federal and state securities laws
(including the delivery of investment representation letters and legal opinions
reasonably satisfactory to the Company, if such are requested by the Company);
provided, however, that notwithstanding the foregoing, this Warrant may be
transferred to Holder's parent company or to an affiliate company as part of a
merger or consolidation and such transfer shall not count as the one permitted
transfer referred to above. The Company shall issue and deliver to the
transferee a new Warrant representing the Warrant so transferred. Upon any
partial transfer, the Company will issue and deliver to Holder a new Warrant
with respect to the Warrant not so transferred. Holder shall not have any right
to transfer any portion of this Warrant to any direct competitor of the Company.

                                       6.

<PAGE>

11. NO FRACTIONAL SHARES. No fractional share of Series B Preferred Stock will
be issued in connection with any exercise hereunder, but in lieu of such
fractional share the Company shall make a cash payment therefor upon the basis
of the Warrant Price then in effect.

12. CHARGES, TAXES AND EXPENSES. Issuance of certificates for shares of Series B
Preferred Stock upon the exercise of this Warrant shall be made without charge
to the Holder for any United States or state of the United States documentary
stamp tax or other incidental expense in reject of the issuance of such
certificate, all of which taxes and expenses shall be paid by the Company, and
such certificates shall be issued in the name of the Holder.

13. NO SHAREHOLDER RIGHTS UNTIL EXERCISE. This Warrant does not entitle the
Holder hereof to any voting rights or other rights as a shareholder of the
Company prior to the exercise hereof.

14. REGISTRY OF WARRANT. The Company shall maintain a registry showing the name
and address of the registered Holder of this Warrant. This Warrant may be
surrendered for exchange or exercise, in accordance with its terms, at such
office or agency of the Company, and the Company and Holder shall be entitled to
rely in all respects, prior to written notice to the contrary, upon such
registry.

15. LOSS, THEFT, DESTRUCTION OR MUTILATION OF WARRANT. Upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of this Warrant, and, in the case of loss, theft, or
destruction, of indemnity reasonably satisfactory to it, and, if mutilated, upon
surrender and cancellation of this Warrant, the Company will execute and deliver
a new Warrant, having terms and conditions substantially identical to this
Warrant, in lieu hereof.

16.      MISCELLANEOUS.

         (a) ISSUE DATE. The provisions of this Warrant shall be construed and
shall be given effect in all respect as if it had been issued and delivered by
the Company on the date hereof.

         (b) SUCCESSORS. This Warrant shall be binding upon any successors or
assigns of the Company.

         (c) GOVERNING LAW. This Warrant shall be governed by and construed in
accordance with the laws of the State of California.

         (d) HEADINGS. The headings used in this Warrant are used for
convenience only and are not to be considered in construing or interpreting this
Warrant.

         (e) SATURDAYS, SUNDAYS, HOLIDAYS. If the last or appointed day for the
taking of any action or the expiration of any right required or granted herein
shall be a Saturday or a Sunday or shall be a legal holiday in the State of
California, then such action may be taken or such right may be exercised on the
next succeeding day not a legal holiday.

17. NO IMPAIRMENT. The Company will not, by amendment of its Articles of
Incorporation or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such

                                       7.

<PAGE>

terms and in the taking of all such action as may be necessary or appropriate in
order to protect the rights of the Holder hereof against impairment.

18. ADDRESSES. Any notice required or permitted hereunder shall be in writing
and shall be mailed by overnight courier, registered or certified mail, return
receipt required, and postage pre-paid, or otherwise delivered by hand or by
messenger, addressed as set forth below, or at such other address as the Company
or the Holder hereof shall have furnished to the other party.

         If to the Company:         Intra Biotics Pharmaceuticals, Inc
                                    816 Kifer Road
                                    Sunnyvale, CA 94086
                                    Attn: Chief Financial Officer

         If to the Holder:          Lease Management Services, Inc.
                                    2500 Sand Hill Road, Ste 101
                                    Menlo Park, CA 94025
                                    Attn: Barbara B. Kaiser, EVP/GM

         IN WITNESS WHEREOF, Kenneth J. Kelley has caused this Warrant to be
executed by its officers thereunto duly authorized.

Dated as of July 20, 1995.

                                                      /s/ Kenneth J. Kelley
                                                 -------------------------------
                                                 By: Kenneth J. Kelley
                                                    ----------------------------
                                                 Title: President and CEO
                                                       -------------------------

                                       8.<PAGE>

                                                                EXHIBIT 10.1(a)
                              EMPLOYMENT AGREEMENT

    EMPLOYMENT AGREEMENT  ("Agreement") made and entered as of September 24,
1999, by and among Media Vision Productions, Inc. (the "Company"), a Deleware
corporation, and John P. Sgarlat
(the "Executive").

                                   BACKGROUND

    The parties desire to enter into an employment agreement and to set forth
herein the terms and conditions of the Executive's employment by the Company.
Accordingly, in consideration of the mutual covenants and agreements set forth
herein and the mutual benefits to be derived here from, and intending to be
legally bound hereby, the Company and the Executive agree as follows:

    1. EMPLOYMENT.

      (a) DUTIES.  The Company shall employ the Executive, on the terms set
forth in this Agreement, as Chief Executive Officer/Chairman of the Board of
Directors. The Executive accepts such employment with the Company and shall
perform and fulfill such duties as are reasonable and necessary for such
position, subject to the Board of Directors of the Company (the "Board"), for
the Company and its subsidiaries, devoting his best efforts to the performance
and fulfillment of his duties and to the advancement of the interests of the
Company, subject only to the direction, approval, control and directives of the
Board.

      (b) PLACE OF PERFORMANCE. In connection with his employment by the
Company, the Executive shall be based in the West Palm Beach, FL metropolitan
area, except for required travel on Company business.

    2. TERM.

    The Executive's employment under this Agreement shall be for a five-year
term (the "Term") commencing as of September 24, 1999 (the "Commencement Date")
and shall continue uninterrupted for the Term. Each year, on the anniversary
date of the Commencement Date, the Term shall be extended for an additional
year, the effect of which is intended by the parties to be that there shall
always be a full five-year Term outstanding under this Agreement.

    3. COMPENSATION.

      (a) BASE SALARY. During the Term, the Executive shall be entitled to
receive annual salary as follows:

       (1) for the year ending September 24, 2000, $240,000;

       (2) for the year ending September 24, 2001, $264,000;

       (3) for the year ending September 24, 2002, $290,400, which shall be the
           base salary (the "Base Salary") for the remaining Term, payable in
           installments at such times as the Company customarily pays its other
           senior executive employees (but in any event no less often than
           monthly).

      (b) Each year thereafter, for the Term, the Executive shall receive an
increase in Base Salary of at least ten percent (10%)(but which may be greater
in the determination of the Compensation Committee) of the current Base Salary,
which increase shall be added to the then-current Base Salary to become the new
Base Salary for the purposes for this Agreement.

      (c) In the event of a change in control such as would require the Company
to file a Form 8-K with the Securities and Exchange Commission if the Company
was a reporting company, the Executive shall be entitled to a lump sum payment
equal to the Base Salary, with minimum ten percent (10%) increases each year,
for the remaining Term, plus a lump sum bonus equal to five times the largest
bonus paid to Executive under this Agreement.

                                       1
<PAGE>
      (d) BONUS.  Executive shall receive an annual bonus in accordance with a
Company Bonus Plan adopted by the Compensation Committee of the Board.

    4. HEALTH INSURANCE AND OTHER BENEFITS.

    During the Term, the Executive shall be entitled to all employee benefits
offered by the Company to its senior executives and key management employees,
including, without limitation, all pension, profit sharing, retirement, stock
option, salary continuation, deferred compensation, disability insurance,
hospitalization insurance, major medical insurance, medical reimbursement,
survivor income, life insurance or any other benefit plan or arrangement
established and maintained by the Company, subject to the rules and regulations
then in effect regarding participation therein. In addition, the Company shall
procure and fund for Executive a life insurance policy in the amount of one
million dollars ($1,000,000), with a beneficiary to be named by Executive.

    5. REIMBURSEMENT OF EXPENSES.

    The Executive shall be reimbursed for all items of travel, entertainment and
miscellaneous expenses which the Executive reasonably incurs in connections with
the performance of his duties hereunder, provided that the Executive submit to
the Company such statements and other evidence supporting said expenses as the
Company may reasonably require.

    6. AUTOMOBILE ALLOWANCE.

    The Company shall pay Executive a monthly autombile allowance of seven
hundred dollars ($700) for the first year of this Agreement, eight hundred
dollars ($800) per month for the second year and one thousand dollars ($1,000)
per month thereafter, subject to increase by the Board.

    7. OPTIONS: GRANT OF SHARES.

      (a) Upon the executive of this Agreement, the Company will issue to
Executive options to purchase at least two hundred thousand (200,000) shares
(the "Shares") of the Company's common stock $0.08 par value, exercisable at the
price of $0.625 per share. These options shall expire seven years from the date
hereof and shall vest as follows:

       (i) sixty-six thousand, six hundred and sixty-six (66,666) shares as of
           April 1, 2000;

       (ii) sixty-six thousand, six hundred and sixty-six (66,666) shares as of
           September 30, 2000;

       (iii) sixty-six thousand, six hundred and sixty-eight (66,668) shares as
           of March 31, 2000;

Options will be exercisable upon vesting. In the event of a change in control
such that would require the Company to file a Form 8-K with the Securities and
Exchange Commission if the Company was a reporting company, all unvested options
will be immediately exercisable. Options may be execised by the Executive giving
the Company a note equal to the exercise price of the options exercised, which
shall bear interest at a floating rate equal to the Federal Funds Rate published
in the Wall Street Journal as adjusted from time to time.

        (b) The Executive will also be eligible to participate in the 1999 Stock
    Option Plan when, as and if approved by the Board. Eligibilty in no way
    creates an obligation on the part of the Company to issue options to the
    Executive, which shall be in the sole and absolute discretion of the
    Compensation Committee of the Board.

        (c) Upon execution of this Agreement, Executive shall receive a grant of
    three million (3,000,000) shares of the Company's common stock.

    8. VACATIONS.

    The Executive shall be entitled to the number of paid vacation days in each
calendar year determined by the Company from time to time for its senior
executive officers, but not less than four (4) weeks in any

                                       2
<PAGE>
calendar year (prorated in any calendar year during which the Executive is
employed hereunder for less than the entire year in accordance with the number
of days in such calendar year during which he is so employed). The Executive
shall also be entitled to all paid holidays given by the Company to its senior
executive officers.

    9. TERMINATION OF EMPLOYMENT.

      (a) DEATH OF TOTAL DISABILITY.  In the event of the death of the Executive
during the Term, this Agreement shall terminate as of the date of the
Executive's death. Salary for the remaining Term shall be paid to Executive's
beneficiary or estate, and all health insurance benefits for Executive's family
shall be continued for at least two years following the Executive's death. In
the event of the Total Disability (as that term is defined below) of the
Executive for any consecutive twelve months during the Term, the Company shall
have the right to terminate this Agreement by giving the Executive thirty (30)
days' prior written notice thereof, and upon the expiration of such thirty (30)
day period, the Executive's employment under this Agreement shall terminate. In
the event of such termination, the salary for the remaining Term shall be paid
to Executive. If the Executive shall resume his duties within (30) days after
receipt of such a notice of termination, this Agreement shall continue in full
force and effect. Upon termination of this Agreement under this Section 9 (a),
the Company shall have no further obligations or liabilities under this
Agreement, except to pay to the Executive's estate or the Executive, as the case
maybe, the portion of salary that remains unpaid for the Term, including minimum
increases and continuation of benefits.

    The term "Total Disability", as used herein, shall mean a mental or physical
condition which in the reasonable opinion of an independent medical doctor
selected by the Company renders the Executive unable or incompetent to carry out
the material duties and responsibilities of the Executive under this Agreement
at the time the disabling condition was incurred. If the Executive is covered
under any policy of disability insurance under paragraph 4, the definition of
Total Disability hereunder shall be the definition of that term in such policy.

    10. NO MITIGATION.

    The Executive shall not be required to mitigate the amount of any payment or
benefit provided for in this Agreement by seeking by seeking other employment or
otherwise, nor shall the amount of any payment provided for in this Agreement be
reduced by any compensation earned by the Executive as a result of his
employment by another employer.

    11. RESTRICTIVE COVENANT.

      (a) COMPETITION.  Executive undertakes and agrees that until two years
after termination of this Agreement, he will not compete, directly or
indirectly, or participate as a director, officer, employee, consultant agent,
consultant, representative or otherwise, or as a stockholder, partner or joint
venturer, or have any direct or indirect financial interest, including, without
limitation, the interest of a creditor, in any business competing directly or
indirectly with the business of the Company or any of its subsidiaries.

      (b) TRADE SECRETS. During the Term hereof and after termination for any
reason, Executive shall not disclose, divulge, copy or otherwise use any trade
secret of the Company or its subsidiaries, it being acknowledged that all such
information and materials complied or obtained by or disclosed to Executive
while employed by the Company or its subsidiaries hereunder or otherwise are
confidential and the exclusive property of the Comapny and its subsidiaries.

      (c) INJUNCTIVE RELIEF. The parties hereto agree that the remedy at law for
any breach of the provisions of this paragraph 11 will be inadequate and that
the Company or any of its subsidiaries or other successors or assigns shall be
entitled to injunctive relief without bond. Such injunctive relief shall not be
exclusive, but shall be in addition to any other rights and remedies Company or
any of its subsidiaries or thier successor or assigns might have for such
breach.

                                       3
<PAGE>
      (d) SCOPE OF COVENANT. Should the duration, goegraphical area or range or
proscribed activities contained in subparagraph (a) above be held unreasonable
by any court of competent jurisdiction, then such duration, geographical areaa
of range of proscribed activities shall be modified to such degree as to make it
or them reasonable and enforceable.

    12. INDEMITY.

    The Company shall indemnify and hold the Executive harmless to the maximum
extent permitted by law against any claim, action, demand, loss, damage, cost,
expense, liability or penalty arising out of any acti, failure to act, omission
or decision by him while performing services as an officer, director or employee
of the Company, other than act, omission or decision by the Executive which is
not in good faith and is without his reasonable belief that same is, or was, in
the best interests of the Company. To the extent permitted by law, the Company
shall pay all attorney's fees, expenses and costs actually incurred by the
Executive in connection with the defense of any of the claims referenced herein.

    13. MISCELLANEOUS.

      (a) NOTICES. Any notice, demand or communication required or permitted
under this Agreement shall be in writing and shall either be hand-delivered to
the other party or mailed to the addresses set forth below by registered or
certified mail, return receipt requested, or sent by overnight express mail or
courier or facsimile to such address, if a party has a facsimile machine. Notice
shall be deemed to have been given and received when so hand-delivered or after
three business days when so deposited in the U.S. Mail, or when transmitted and
received by facsimile or sent by express mail properly addressed to the other
party.

The addresses are:

To the Company:
Media Vision Productions Inc.
105 S. Narcissus Avenue
West Palm Beach, FL 33401

To the Executive:
Mr. John P. Sgarlat
2490 Players Court
Wellington, FL 33414-1017

The foregoing addresses may be changed at any time by written notice given in
the manner herein provided.

      (b) INTEGRATION; MODIFICATION. This Agreement constitues the entire
understanding and agreement between the Company and the executive regarding its
subject matter and supersedes all prior negotiations and agreements, whether
oral or written, between them with respect to its subject matter. This Agreement
may not be modified except by a written agreement signed by the Executive and a
duly authorized officer of the Company.

      (c) ENFORCEABILITY. If any provision of this Agreement shall be invalid or
unenforceable, in whole or in part, such provision shall be deemed to be
modified or restricted to the extent and in the manner necessary to render the
same valid and enforceable, or shall be deemed excises from this Agreement, as

                                       4
<PAGE>
the case may require, and this Agreement shall be construed and enforced to the
maximum extent permitted by law as if such provision had not been originally
incorporated herein, as the case may be.

      (d) BINDING EFFECT. This Agreement shall be binding upon and inure to the
benefit of the parties, including and their respective heirs, executors,
successors and assigns, except that this Agreement may not be assigned by the
Executive.

      (e) WAIVER OF BREACH. No waiver by either party of any condition or of the
breach by the other of any term or covenant contained in this Agreement, whether
by conduct or otherwise, in any one or more instances shall be deemed or
construed as a further or continuing waiger of any such condition or breach or
waiver of any other condition, or the breach of any other term or covenant set
forth in this Agreement. Moreover, the failure of either party to exercise any
right hereunder shall not bar the later exercise thereof.

      (f) GOVERNING LAW AND INTERPRETATION. This Agreement shall be governed by
the internal laws of Delaware. Each of the parties agrees that he or it, as the
case may be, shall deal fairly and in good faith with the other party in
performing, observing and complying with the covenants, promises, duties,
obligations, terms and conditions to be performed, observed or complied with by
him or it, as the case may be, hereunder; and that this Agreement shall be
interpreted, construed and enforced in accordance with the foregoing covenant
notwithstanding any law to the contrary.

      (g) HEADINGS. The headings of the various sections and paragraphs have
been included herein for convenience only and shall not be considered in
interpreting this Agreement.

      (h) COUNTERPARTS. This Agreement may be executed in several counterparts,
each of which shall be deemed to be an original but all of which together will
constitute one and the same instrument.

        IN WITNESS WHEREOF, this Agreement has been executed by the Executive
and on behalf of the Company by its duly authorized officer(s) on the date first
above written.

<TABLE>
<S>   <C>                                         <C>
MEDIA VISION PRODUCTIONS, INC.

                 /s/ WILLIAM CAMPBELL
      ------------------------------------------
                   William Campbell
By:

                  /s/ JOHN P. SGARLAT
      ------------------------------------------
                    John P. Sgarlat
</TABLE>

                                       5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00000-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00000-of-00352.parquet"}]]